Skip to main content

Table 1 Patient characteristics in different cohorts

From: Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity

Characteristics

Prone volumetric modulated arc therapy group (n = 12)

Supine box group (n = 6)

Age (years)

  

   Median

52.5

57.5

   Range

38 to 72

53 to 71

Sex

  

   Male

7

5

   Female

5

1

Clinical tumor stage

  

   T2

1

0

   T3

8

5

   T4

3

1

Clinical node stage

  

   N0

2

2

   N1

2

4

   N2

8

0

Clinical stage

  

   IIA

2

2

   IIIB

6

2

   IIIC

4

0

   IVA

0

2

Distance from the anal verge

  

   < 5 cm

5

1

   5 to 10 cm

7

4

   ≥ 10 cm

0

1

Chemotherapy

  

   Bevacizumab + FOLFOX (leucovorin, fluorouracil, and oxaliplatin)

11

6

   Bevacizumab +5-fluorouracil

1

0

Surgical type

  

   Lower anterior resection

9

3

   Abdominoperineal resection

3

1